{"created":"2023-05-15T14:36:08.747161+00:00","id":46528,"links":{},"metadata":{"_buckets":{"deposit":"96b1270a-5843-4965-a12f-0de8020a960b"},"_deposit":{"created_by":1,"id":"46528","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"46528"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00046528","sets":["1"]},"author_link":["463685","463689","463687","463688","463686","463692","463690","463694","463691","463693","463684"],"item_8_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2012-07","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"7","bibliographicPageEnd":"947","bibliographicPageStart":"944","bibliographicVolumeNumber":"39","bibliographic_titles":[{"bibliographic_title":"Nuclear Medicine and Biology"}]}]},"item_8_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Objectives\n\\nTo investigate the potential of monoclonal antibody (mAb) RM2 as a ligand for a radioimmunotracer for prostate cancer imaging.\n\\nMethods\n\\nLabeling was conducted with mAb RM2 and 125I using the chloramine-T method. The cell study was conducted with PC-3 and LNCaP, which are prostate cancer cell lines, and MCF-7, which is a breast cancer cell line. The cells were treated or untreated with unlabeled mAb RM2 to block the haptoglobin-B chains expressed on the surface of the prostate cancer cells. 125I-mAb RM2 was added into the cell culture media and cellular uptake of 125I-mAb RM2 was evaluated at 1, 3 and 6 hours of incubation. For the in vivo biodistribution study, PC-3 cells were implanted in athymic male mice. The animals were injected intravenously with 125I-mAb RM2. At 24, 48 and 72 hours after tracer injection, the animals were sacrificed and the activity levels of blood and tissue samples were determined.\n\\nResults\n\\nThe uptake of 125I-mAb RM2 in the PC-3 and LNCaP cells increased according to the incubation time, while the uptake of 125I-mAb RM2 in MCF-7 cells did not show any increase up to 6 hours. The increase of 125I-RM2 uptake was not observed when the PC-3 and LNCaP cells were pre-treated with unlabeled RM2. In the biodistribution studies, 125I-mAb RM2 showed marked uptake into the implanted PC-3 cells. In PC-3 tumor-bearing mice, the tumor muscle ratio of 125I-RM2 was increased for up to 72 hours in a time-dependent manner.\n\\nConclusions\n\\n125I-mAb RM2 showed excellent prostate cancer cell targeting in vitro and in vivo. Therefore, mAb RM2 seems to be a potential candidate for an immunoligand for prostate cancer imaging.","subitem_description_type":"Abstract"}]},"item_8_relation_14":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1016/j.nucmedbio.2012.05.008","subitem_relation_type_select":"DOI"}}]},"item_8_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0969-8051","subitem_source_identifier_type":"ISSN"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Hasegawa, Yoko"}],"nameIdentifiers":[{"nameIdentifier":"463684","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Oyama, Nobuyuki"}],"nameIdentifiers":[{"nameIdentifier":"463685","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Nagase, Keiko"}],"nameIdentifiers":[{"nameIdentifier":"463686","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Arai, Yoichi"}],"nameIdentifiers":[{"nameIdentifier":"463687","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Furukawa, Takako"}],"nameIdentifiers":[{"nameIdentifier":"463688","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Fujibayashi, Yasuhisa"}],"nameIdentifiers":[{"nameIdentifier":"463689","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Welch, Michael"}],"nameIdentifiers":[{"nameIdentifier":"463690","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yokoyama, Osamu"}],"nameIdentifiers":[{"nameIdentifier":"463691","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"et.al"}],"nameIdentifiers":[{"nameIdentifier":"463692","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"古川 高子","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"463693","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"藤林 康久","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"463694","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Monoclonal antibody RM2 as a potential ligand for a new immunotracer for prostate cancer imaging","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Monoclonal antibody RM2 as a potential ligand for a new immunotracer for prostate cancer imaging"}]},"item_type_id":"8","owner":"1","path":["1"],"pubdate":{"attribute_name":"公開日","attribute_value":"2013-04-15"},"publish_date":"2013-04-15","publish_status":"0","recid":"46528","relation_version_is_last":true,"title":["Monoclonal antibody RM2 as a potential ligand for a new immunotracer for prostate cancer imaging"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T23:50:41.696646+00:00"}